The secondary structure of apolipoproteins in human HDL3 particles after chemical modification of their tyrosine, lysine, cysteine or arginine residues. A Fourier transform infrared spectroscopy study.
Fourier transform infrared spectra of apolipoprotein E-depleted human HDL3 have been obtained in H2O and 2H2O buffers. The absorption bands in the protein amide I and amide II regions (1700-1500 cm-1) were assigned to alpha-helical, disordered and beta-strand/beta-turn structures of apolipoproteins A-I and A-II (apoA-I and apoA-II), the apolipoprotein constituents of HDL3. Modification of HDL3 by tetranitromethane (TNM) treatment, acetylation, reduction plus alkylation and 1,2-cyclohexanedione treatment derivatised tyrosine, lysine, cysteine and arginine residues, respectively, and caused alteration of the secondary structure of the HDL3 apolipoproteins to different extents. Each of the chemical modifications caused changes in the frequency of bands associated with beta-strands/beta-turns, but only TNM treatment of HDL3, as judged by the second- and fourth-derivative spectra, resulted in a shift of the band assigned to the alpha-helical structure of the proteins. In agreement with other workers, only TNM treatment of HDL3 particles was found to inhibit their binding by high-affinity cell membrane receptors. It is proposed, therefore, that receptor recognition of HDL3 particles is dependent on conservation of the alpha-helix structures within apoA-I and apoA-II, and that beta-strand/beta-turn structures are not involved. This conclusion is consistent with the predominance of amphipathic alpha-helical structures in both apolipoproteins and with the relaxed specificity of the receptors which are thought to recognise both apoA-I and apoA-II.
Herzyk
E
E
Department of Protein and Molecular Biology, Royal Free Hospital School of Medicine, London, U.K.
Owen
J S
JS
Chapman
D
D
D000215:Acylation; D000478:Alkylation; D000596:Amino Acids / Q000378:metabolism*; D001057:Apolipoproteins E / Q000378:metabolism; D001120:Arginine / Q000378:metabolism; D003512:Cyclohexanones; D003545:Cysteine / Q000378:metabolism; D005583:Fourier Analysis; D006801:Humans; D008075:Lipoproteins, HDL; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D008239:Lysine / Q000378:metabolism; D010084:Oxidation-Reduction; D011487:Protein Conformation / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000032:analysis / Q000187:drug effects; D013055:Spectrophotometry, Infrared; D013774:Tetranitromethane; D014443:Tyrosine / Q000378:metabolism
D000596:Amino Acids; D001057:Apolipoproteins E; D003512:Cyclohexanones; D008075:Lipoproteins, HDL; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D011956:Receptors, Cell Surface; C025121:apolipoprotein E-rich HDL; D014443:Tyrosine; C018031:1,2-cyclohexanedione; D001120:Arginine; D013774:Tetranitromethane; D008239:Lysine; D003545:Cysteine